Home › Funds › Lynx1 Capital Management LP › STOK

Lynx1 Capital Management LP position in STOK

STOKE THERAPEUTICS INC · Health Care

Lynx1 Capital Management LP reported holding 4,038,404 shares of STOK (STOKE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$132.1M, representing 15.27% of its reported portfolio and ranking #3 among its reported holdings. Lynx1 Capital Management LP has disclosed STOK holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)4.04M sh
Reported value held$132.14M
Portfolio Weight15.27%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lynx1 Capital Management LP's STOK position evolved

Lynx1 Capital Management LP first disclosed a stake in STOK in Q3 2023 at 1,710,154 shares (US$6.7M). The position peaked in Q4 2025 at 5,404,674 shares, worth US$171.5M. Across 12 filings, Lynx1 Capital Management LP increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 4,038,404 shares valued at US$132.1M — a reduction of -725,269 shares quarter over quarter.. Notable position changes include a 73% increase in Q4 2023 (shares rose 157% over the following quarter), a 25% increase in Q1 2024 (shares were roughly flat over the following quarter), a 40% increase in Q2 2024 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.71M $6.74M New
Q4 2023 2.96M $15.55M Add
Q1 2024 3.70M $49.91M Add
Q2 2024 5.19M $70.05M Add
Q3 2024 5.19M $63.75M Hold
Q4 2024 5.19M $57.21M Hold
Q1 2025 5.29M $35.19M Add
Q2 2025 5.40M $61.34M Add
Q3 2025 5.40M $109.88M Hold
Q4 2025 5.40M $171.54M Hold
Q1 2026 4.76M $155.11M Reduce
Q2 2026 4.04M $132.14M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About STOK and 13F data

STOK (STOKE THERAPEUTICS INC) is a Health Care company. 52 other funds we track also report a position in STOK — the largest reported positions include RTW INVESTMENTS, LP (US$184.0M), Redmile Group, LLC (US$129.1M), BAKER BROS. ADVISORS LP (US$109.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding STOK

All STOK fund holders →

FAQ

How long has Lynx1 Capital Management LP held STOK?

Lynx1 Capital Management LP has disclosed STOK holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Lynx1 Capital Management LP's current position in STOK?

As of Q2 2026, Lynx1 Capital Management LP holds 4.04M shares of STOK (STOKE THERAPEUTICS INC), valued at $132.14M, representing 15.27% of its reported portfolio and ranking #3.

Has Lynx1 Capital Management LP been buying or selling STOK?

In the latest 13F filing (Q2 2026), Lynx1 Capital Management LP reduced its position in STOK. The position peaked in Q4 2025 at 5.40M shares.

Which other funds hold STOK?

Other major institutional holders of STOK include RTW INVESTMENTS, LP, Redmile Group, LLC, BAKER BROS. ADVISORS LP, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.